Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5816 - Streamlining Multi-omic and Artificial Intelligence Analysis Through Interrogative Biology and BAIcis for Translational Precision Medicine Applications in Clinical Oncology

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Leonardo Rodrigues

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

L. Rodrigues1, M.A. Kiebish2, G. Miller1, L. Zhang1, V. Vemulapalli1, V.K. Vishnudas3, R. Sarangarajan3, N.R. Narain4, V.R. Akmaev1

Author affiliations

  • 1 Analytics, BERG, LLC, 01701 - Framingham/US
  • 2 Precision Medicine, BERG, LLC, 01701 - Framingham/US
  • 3 Biosystems, BERG, LLC, 01701 - Framingham/US
  • 4 Biosystems, Analytics, & Precision Medicine, BERG, LLC, 01701 - Framingham/US
More

Resources

Abstract 5816

Background

Despite advances in high throughput molecular technologies, increased availability of clinical information, and access to complex population level datasets, translating this information into causal and actionable clinical guidance in oncology remains a challenge.

Methods

The BERG Interrogative Biology platform deconstructs the established paradigm by using patient biology to guide the entire drug development process from R&D to clinic, leading to improved clinical outcome. In order to properly characterize the molecular phenotype of patients or disease states, this platform allows for systematic interrogation of each biological sample by high-throughput multi-omic technologies such as proteomics, lipidomics and metabolomics. This is then combined with further analytical methods that allows for assessment of sample quality through statistical, environmental/demographic influence, sample handling, and pharmacological impact markers to elucidate causal molecular signal from inherent noise.

Results

BERG ETL System uses a proprietary data-driven algorithm to automatically extract, normalize, correct eventual systematic errors, align and unify all data sources and types, outputting a harmonized molecular and/or clinical profile, which can be used for summary reports such as patient dashboards, standard analysis such as statistics and machine learning, and to be analyzed by BERG’s Artificial Intelligence (AI) Technology, bAIcis. When applied to clinical trial information, bAIcis uses a multi-layer method to identify clinical and molecular markers that can stratify patients based on trial outcomes such as “Response to Treatment”, “Quality of Life” or “Adverse Events” as well as identification of disease drivers.

Conclusions

Using this approach a comprehensive understanding of causal drivers, predictive biomarkers aligned with therapeutic benefit, and identification of adverse event populations in cancer indications can be elucidated. This is streamlined through an AI driven platform based on quality metric to support precision medicine in oncology drug development.

Clinical trial identification

Legal entity responsible for the study

Berg, LLC.

Funding

Berg, LLC.

Editorial Acknowledgement

Khampaseuth Thapa, Berg, LLC.

Disclosure

L. Rodrigues, M.A. Kiebish, G. Miller, L. Zhang, V. Vemulapalli, V.K. Vishnudas, V.R. Akmaev: Employee, and stock owner: Berg, LLC. R. Sarangarajan: Co-founder, employee and stock owner: Berg, LLC. N.R. Narain: Co-founder, President, CEO, and stock owner: Berg, LLC.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings